AU2018213418A1 - Passive antibody dependent cell-mediated activation - Google Patents

Passive antibody dependent cell-mediated activation Download PDF

Info

Publication number
AU2018213418A1
AU2018213418A1 AU2018213418A AU2018213418A AU2018213418A1 AU 2018213418 A1 AU2018213418 A1 AU 2018213418A1 AU 2018213418 A AU2018213418 A AU 2018213418A AU 2018213418 A AU2018213418 A AU 2018213418A AU 2018213418 A1 AU2018213418 A1 AU 2018213418A1
Authority
AU
Australia
Prior art keywords
cells
protein
cell
igg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018213418A
Other languages
English (en)
Inventor
Michael Caligiuri
Hongsheng DAI
Jianhua Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of AU2018213418A1 publication Critical patent/AU2018213418A1/en
Assigned to OHIO STATE INNOVATION FOUNDATION reassignment OHIO STATE INNOVATION FOUNDATION Request for Assignment Assignors: CALIGIURI, MICHAEL, DAI, Hongsheng, OHIO STATE INNOVATION FOUNDATION, YU, JIANHUA
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018213418A 2017-01-30 2018-01-30 Passive antibody dependent cell-mediated activation Abandoned AU2018213418A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452111P 2017-01-30 2017-01-30
US62/452,111 2017-01-30
PCT/US2018/016035 WO2018140974A1 (en) 2017-01-30 2018-01-30 Passive antibody dependent cell-mediated activation

Publications (1)

Publication Number Publication Date
AU2018213418A1 true AU2018213418A1 (en) 2019-06-20

Family

ID=62979661

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018213418A Abandoned AU2018213418A1 (en) 2017-01-30 2018-01-30 Passive antibody dependent cell-mediated activation

Country Status (6)

Country Link
US (1) US11459378B2 (https=)
EP (1) EP3573640A4 (https=)
JP (1) JP2020505418A (https=)
CN (1) CN110536699A (https=)
AU (1) AU2018213418A1 (https=)
WO (1) WO2018140974A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
KR20220035457A (ko) * 2019-07-21 2022-03-22 글락소스미스클라인 바이오로지칼즈 에스.에이. 치료 바이러스 백신
CN111411079B (zh) * 2020-03-27 2025-12-12 北京时合生物科技有限公司 细胞培养方法、改造抗体、细胞培养基、细胞产品及其应用
CN114621356A (zh) * 2022-05-17 2022-06-14 康希诺生物股份公司 以il18为分子佐剂的带状疱疹亚单位疫苗
US20260097088A1 (en) * 2022-10-17 2026-04-09 Research Institute At Nationwide Children's Hospital Macrophage polarizing oncolytic herpes simplex virus for cancer therapy
EP4724093A1 (en) * 2023-06-09 2026-04-15 Cornell University Vaccines for human cytomegalovirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
US9758794B2 (en) * 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
ES2688978T3 (es) * 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
CA2808154A1 (en) * 2010-08-13 2012-02-16 Medimmmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
US9676857B2 (en) * 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
CN105669838B (zh) * 2014-12-04 2020-10-16 厦门大学 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体

Also Published As

Publication number Publication date
JP2020505418A (ja) 2020-02-20
EP3573640A4 (en) 2021-04-28
WO2018140974A1 (en) 2018-08-02
EP3573640A1 (en) 2019-12-04
CN110536699A (zh) 2019-12-03
US20200040064A1 (en) 2020-02-06
US11459378B2 (en) 2022-10-04

Similar Documents

Publication Publication Date Title
US11459378B2 (en) Passive antibody dependent cell-mediated activation
JP6895374B2 (ja) 免疫チェックポイントモジュレーターの発現用腫瘍溶解性ウイルス
JP7560356B2 (ja) 急性骨髄性白血病を治療するためのｆｌｔ３ ｃａｒ－ｔ細胞及びｆｌｔ３阻害剤の使用
KR20170120104A (ko) 암 또는 감염의 치료를 위한 조합 제조물
JP2023126868A (ja) 改変オルトポックスウイルスベクター
US20230357793A1 (en) Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
CN113164538B (zh) 修饰的溶瘤病毒、其组合物和用途
US20240269203A1 (en) Oncolytic virus and uses thereof
US20240374719A1 (en) Novel combinations of antibodies and uses thereof
CN119233986A (zh) 包含抗体或者包含含有抗体的Fc部分的含Fc融合蛋白的疫苗
CN114657150A (zh) 用于改善免疫疗法的重组溶瘤腺病毒及其应用
JP2025526369A (ja) Ｐｄ－１／ｐｄ－ｌ１阻害剤を有するインターロイキン１２を発現する組換えウイルスの組み合わせ
TWI666321B (zh) 用於癌症治療的溶瘤性單純皰疹病毒（ｏＨＳＶ）專性載體及其建構體的建構
US20250339481A1 (en) Method of delivery of fusogenic oncolytic virus and therapeutic molecules
TWI868410B (zh) 用於腦腫瘤治療的溶瘤性ｉ型單純皰疹病毒
WO2025185740A1 (zh) 一种修饰的溶瘤病毒及其组合物
CN118176016A (zh) 抗体的新型组合及其用途
WO2024262576A1 (ja) 免疫刺激型ヘルペスウイルス
HK40106416A (zh) 抗体的新型组合及其用途
AU2023401158A1 (en) Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
Lukacher et al. Costimulation Requirements for Antiviral

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OHIO STATE INNOVATION FOUNDATION

Free format text: FORMER APPLICANT(S): CALIGIURI, MICHAEL; OHIO STATE INNOVATION FOUNDATION; DAI, HONGSHENG; YU, JIANHUA

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted